First in human implantation of a novel transfemoral self-expanding transcatheter heart valve to treat pure aortic regurgitation
The first case of a novel JenaValve design using the transfemoral approach in a 78 year old female patient with pure aortic regurgitation is described in this article.
State of the art: coronary angiography
In the early days of coronary angiography, the precise quantification of luminal narrowing was challenging. The introduction of balloon angioplasty (percutaneous transluminal coronary angioplasty [PTCA]) by Andreas Grüntzig in 1977 was perhaps the greatest incentive to the development of quantitative coronary angiography (QCA). QCA has played a crucial role in evaluating interventional techniques and assessing the results of new technologies.
Role of intravascular imaging in the evolution of percutaneous coronary intervention: a 30-year review
It has been 40 years since percutaneous coronary intervention (PCI) was introduced into the clinical setting. Over these years significant advances in device technology and the invention of new therapeutic strategies have broadened its applications in the clinical arena, rendering this treatment the first-line therapy for patients with obstructive coronary artery disease.
State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives
Evidence from studies published more than 10 years ago suggested that patients receiving first-generation drug-eluting stents (DES) needed dual antiplatelet therapy (DAPT) for at least 12 months. Current evidence from randomised controlled trials (RCT) reported within the past five years suggests that patients with stable ischaemic heart disease who receive newer-generation DES need DAPT for a minimum of three to six months.
State of the art: 40 years of percutaneous cardiac intervention
There are few areas in medicine where the development of an entire field is perceived to be so closely associated with one individual. Andreas Roland Grüntzig was born in Dresden, Germany, ten weeks before the outbreak of the Second World War on 25 June 1939. Learn more about his influences on percutaneous cardiac intervention and angioplasty.
How to become an Andreas Grüntzig in the 21st century
The contributions of Andreas Grüntzig to modern medicine are huge, though it may be argued that serendipity accounted for a significant part of his success. He came to Zürich to be a disciple of Robert Hegglin, an internist. Hegglin died shortly after Grüntzig’s arrival, obliging him to find a substitute tutor in the person of Alfred Bollinger, an angiologist, whose diagnostic skills he quickly acquired.
Commemorating the 15-year anniversary of TAVI: insights into the early stages of development, from concept to human application, and perspectives
A. Cribier. shares his experience of cardiac catheterisation in the early 1970s and follow the fascinating evolution of the technology over the past 40 years.
His master’s art, Andreas Grüntzig’s approach to performing and teaching coronary angioplasty
Andreas Roland Grüntzig (1939-1985) was an accomplished clinician and an astute scientist. He was also a practical man endowed with dexterity, smartness, and common sense.
What is it to become an octogenarian 40 years after the first angioplasty?
In 1985, four pioneers, Charles Dotter, Melvin Judkins, Mason Sones, and Andreas Grüntzig died in the same year. They have probably opened a wonderful diagnostic and interventional suite together in heaven.
40 years of angioplasty – remembering patients and pioneers
Less than a century ago, no doctor would dare to touch a human heart. Only five decades ago, the basic therapy for a heart attack was to lie down and bear it.